Center for Cancer Research Seminar - Thurs., Jan. 29
| Event Date: | January 29, 2015 |
|---|---|
| Hosted By: | Purdue University Center for Cancer Research |
| Time: | 11:30 a.m. |
| Location: | Drug Discovery Building - Lobby Conference Room |
Dr. Szyf received his PhD from the Hebrew University and did his postdoctoral fellowship in Genetics at Harvard Medical School. He joined the Department of Pharmacology and Therapeutics at McGill University in Montreal in 1989 and currently holds a James McGill Professorship and GlaxoSmithKline-CIHR Chair in Pharmacology and is a fellow of the Royal Society of Canada. He is the founding co-director of the Sackler Institute for Epigenetics and Psychobiology at McGill and is a Fellow of the Canadian Institute for Advanced Research Experience-based Brain and Biological Development program. Dr. Szyf has been the founder of the first “Pharma” to develop epigenetic pharmacology “Methylgene Inc.” and the first journal in epigenetics “Epigenetics”. Szyf lab has proposed two decades ago that DNA methylation is a prime therapeutic target in cancer and other diseases and has postulated and provided the first set of evidence that the “social environment” early in life can alter DNA methylation launching the emerging field of “social epigenetics”.
2015-01-29 11:30:00 2015-01-29 12:30:00 America/Indiana/Indianapolis Center for Cancer Research Seminar - Thurs., Jan. 29 Dr. Moshe Szyf, the James McGill Professor and GlaxoSmithKline-CIHR Chair in Pharmacology at McGill University will present a seminar entitled "DNA demethylation a mechanism driving cancer and cancer metastasis; therapeutic and diagnostic implications" on Thursday, January 29th at 11:30 a.m. in the Drug Discovery Building's Lobby Conference Room. Drug Discovery Building - Lobby Conference Room